Azimut Capital Management SGR SpA recently announced the acquisition of new stake in Ekso Bionics Holdings Inc. (NASDAQ:EKSO). The institutional investor has increased its shareholding in the Healthcare company by 32.62% to 0.15 million shares with purchase of 35667.0 shares. This fresh investment now brings its stake to 1.91% valued currently at $1.22 million. In addition, Intellectus Partners LLC raised its holdings by 0.11 million to 0.13 million shares. And BlackRock Fund Advisors has lifted its position by 6.86% or 3710.0 shares – to 57767.0 shares.
With over 0.31 million Ekso Bionics Holdings Inc. (EKSO) shares trading Friday and a closing price of $7.30 on the day, the dollar volume was approximately $2.25 million. The shares have shown a negative weekly performance of -6.53% and its price on 07/24/20 gained nearly 1.67%. Currently, there are 5.80M common shares owned by the public and among those 4.32M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for EKSO have a consensus price objective of $12.50. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $12.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Ekso Bionics Holdings Inc. stock is 2.00 for the next 12 months. The average price target is 41.6% above its last price level and an upside to the estimated low will see the stock gain 39.17% over that period. But an upside of 43.85% will see the stock hit the forecast high price target while mean target price for the stock is $12.50.
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 311,113 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Ekso Bionics Holdings Inc. are AZ Multi Asset – Institutional T, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu. AZ Multi Asset – Institutional T owns 0.13 million shares of the company’s stock, all valued at over $1.12 million. The company bought an additional 24000.0 shares recently to bring their total holdings to about 1.76% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 0.58% of the shares outstanding.
Shares of Ekso Bionics Holdings Inc. (NASDAQ: EKSO) opened at $7.13, down -$0.05 from a prior closing price of $7.18. However, the script later closed the day at $7.30, up 1.67%. The company’s stock has a 5-day price change of -6.53% and 84.34% over the past three months. EKSO shares are trading 24.47% year to date (YTD), with the 12-month market performance down to -60.11% lower. It has a 12-month low price of $2.25 and touched a high of $19.05 over the same period. Currently, 0.31 million shares have been traded, compared to an average intraday trading volume of 3.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.22%, 39.84%, and 26.31% respectively.
Institutional ownership of Ekso Bionics Holdings Inc. (NASDAQ: EKSO) shares accounts for 22.20% of the company’s 5.80M shares outstanding. Mutual fund holders own 13.23%, while other institutional holders and individual stakeholders account for 4.36% and — respectively.
It has a market capitalization of $54.31M and a beta (3y monthly) value of 2.02. The earnings-per-share (ttm) stands at -$1.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.32% over the week and 16.43% over the month.
Analysts forecast that Ekso Bionics Holdings Inc. (EKSO) will achieve an EPS of -$0.55 for the current quarter, -$0.52 for the next quarter and -$1.34 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.6 while analysts give the company a high EPS estimate of -$0.51. Comparatively, EPS for the current quarter was -$0.6 a year ago. Earnings per share for the fiscal year are expected to increase by 61.70%, and 35.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Ekso Bionics Holdings Inc. (EKSO) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the EKSO, a number of firms have released research notes about the stock. SunTrust stated their Buy rating for the stock in a research note on October 14, 2016, with the firm’s price target at .